NICHOLAS J GOETSCH
- Type
- Physician · Allopathic & Osteopathic Physicians / Family Medicine
- Where
- WATERLOO, IA
- NPI
- 1740287614
- Received
- $574,403 in 396 records, 2019 to 2025 ($524,784 general, $49,618 research)
- As principal investigator
- $3,590,110 of research payments to others in 142 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 28 | $68,330 |
| 2024 | General payment | 30 | $66,695 |
| 2024 | Research payment | 1 | $1,900 |
| 2023 | General payment | 27 | $47,869 |
| 2023 | Research payment | 2 | $1,900 |
| 2022 | General payment | 57 | $72,403 |
| 2022 | Research payment | 4 | $37,704 |
| 2021 | General payment | 47 | $72,763 |
| 2021 | Research payment | 2 | $8,114 |
| 2020 | General payment | 120 | $114,588 |
| 2019 | General payment | 78 | $82,133 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 180 | $406,857 | 2020–2025 |
| Shire North American Group Inc | 25 | $58,946 | 2019 |
| Eli Lilly and Company | 8 | $47,718 | 2021–2023 |
| Allergan, Inc. | 86 | $27,443 | 2019–2020 |
| ABBVIE INC. | 58 | $16,594 | 2021–2025 |
| Janssen Pharmaceuticals, Inc | 32 | $15,885 | 2019–2022 |
| Kowa Pharmaceuticals America, Inc. | 5 | $920 | 2022 |
| CSL Behring | 1 | $21 | 2019 |
| Genentech USA, Inc. | 1 | $15 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 178 | $464,009 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 31 | $52,040 |
| Research payment | 9 | $49,618 |
| Travel and Lodging | 42 | $5,824 |
| Food and Beverage | 136 | $2,911 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-05 | Takeda Pharmaceuticals U.S.A., Inc. | $2,807 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-05 | Takeda Pharmaceuticals U.S.A., Inc. | $2,807 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-12 | Takeda Pharmaceuticals U.S.A., Inc. | $2,807 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-12 | Takeda Pharmaceuticals U.S.A., Inc. | $2,807 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-16 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | TEFLARO Drug, ANTI-INFECTIVE | 2025 | |
| 2025-10-08 | Takeda Pharmaceuticals U.S.A., Inc. | $2,807 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-08 | Takeda Pharmaceuticals U.S.A., Inc. | $2,807 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-11 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-08-08 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-08 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-04-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-04-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-03-12 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-03-12 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-12 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-12 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-08 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | TEFLARO Drug, ANTI-INFECTIVE | 2025 | |
| 2025-01-17 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-01-17 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-01-15 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2024-12-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-12-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-13 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-13 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-25 | Takeda Pharmaceuticals U.S.A., Inc. | $312 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-01 | ABBVIE INC. | $1,900 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Seve | 2024 | |
| 2024-09-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-09-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-08-22 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | TEFLARO Drug, ANTI-INFECTIVE | 2024 | |
| 2024-08-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-08-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-07-15 | Takeda Pharmaceuticals U.S.A., Inc. | $1,353 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-07-12 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-07-12 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-05-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-05-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-05-06 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | TEFLARO Drug, ANTI-INFECTIVE | 2024 | |
| 2024-04-17 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-04-17 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-03-28 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | TEFLARO Drug, ANTI-INFECTIVE | 2024 | |
| 2024-03-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-03-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-02-14 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-02-14 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-01-17 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-01-17 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-01-05 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | TEFLARO Drug, ANTI-INFECTIVE | 2024 | |
| 2023-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-11-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-11-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-11-07 | ABBVIE INC. | $1,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2023 | |
| 2023-10-25 | ABBVIE INC. | $25 | Travel and Lodging | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2023 | |
| 2023-10-25 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2023 | |
| 2023-10-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-10-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,707 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-20 | Takeda Pharmaceuticals U.S.A., Inc. | $1,955 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-13 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-13 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-16 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2023 | |
| 2023-07-20 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2023 | |
| 2023-07-14 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-07-14 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-06-14 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-06-14 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-05-09 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2023 | |
| 2023-04-18 | ABBVIE INC. | $1,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2023 | |
| 2023-04-07 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-04-07 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-03-29 | ABBVIE INC. | $52 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2023 | |
| 2023-03-06 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2023 | |
| 2023-02-08 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-02-08 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-02-08 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2023 | |
| 2023-01-31 | Eli Lilly and Company | $575 | Research payment | In-kind items and services | A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | 2023 | |
| 2023-01-10 | Eli Lilly and Company | $1,325 | Research payment | In-kind items and services | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 | |
| 2022-12-15 | Kowa Pharmaceuticals America, Inc. | $900 | Consulting Fee | Cash or cash equivalent | Seglentis Drug, Pain Management | 2022 | |
| 2022-12-07 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-12-07 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-12-07 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-11-21 | Eli Lilly and Company | $28,114 | Research payment | Cash or cash equivalent | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2022 | |
| 2022-11-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-11-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-11-04 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-10-05 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-10-05 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-09-20 | ABBVIE INC. | $1,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-09-20 | ABBVIE INC. | $28 | Food and Beverage | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-09-20 | ABBVIE INC. | $16 | Travel and Lodging | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-09-15 | Janssen Pharmaceuticals, Inc | $25 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-09-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-09-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-08-31 | Kowa Pharmaceuticals America, Inc. | $2 | Food and Beverage | Cash or cash equivalent | Seglentis Drug, Pain Management | 2022 | |
| 2022-08-22 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-08-17 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-08-17 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-08-17 | Kowa Pharmaceuticals America, Inc. | $2 | Food and Beverage | Cash or cash equivalent | Seglentis Drug, Pain Management | 2022 | |
| 2022-07-13 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-13 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-13 | Kowa Pharmaceuticals America, Inc. | $6 | Food and Beverage | Cash or cash equivalent | Seglentis Drug, Pain Management | 2022 | |
| 2022-07-12 | Eli Lilly and Company | $419 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2022 | |
| 2022-07-08 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-06-30 | Kowa Pharmaceuticals America, Inc. | $8 | Food and Beverage | Cash or cash equivalent | Seglentis Drug, Pain Management | 2022 | |
| 2022-06-24 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-06-06 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-06-06 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-05-16 | Takeda Pharmaceuticals U.S.A., Inc. | $300 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-05-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-05-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-04-19 | ABBVIE INC. | $1,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-04-19 | ABBVIE INC. | $58 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-04-19 | ABBVIE INC. | $16 | Travel and Lodging | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-04-19 | ABBVIE INC. | $14 | Food and Beverage | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-04-19 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-04-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-04-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-04-08 | Eli Lilly and Company | $4,610 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 | |
| 2022-04-04 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-03-28 | ABBVIE INC. | $1,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-03-28 | ABBVIE INC. | $15 | Travel and Lodging | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-03-28 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-03-09 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-03-08 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-03-08 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-03-08 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-02-15 | Takeda Pharmaceuticals U.S.A., Inc. | $1,303 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-02-07 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-02-07 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-02-03 | Janssen Pharmaceuticals, Inc | $14 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-01-31 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-01-18 | ABBVIE INC. | $1,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-01-18 | ABBVIE INC. | $53 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-01-18 | ABBVIE INC. | $15 | Travel and Lodging | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-01-18 | ABBVIE INC. | $14 | Food and Beverage | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-01-12 | Eli Lilly and Company | $4,561 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2022 | |
| 2022-01-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-01-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2021-12-14 | ABBVIE INC. | $1,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-12-14 | ABBVIE INC. | $62 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-12-14 | ABBVIE INC. | $9 | Travel and Lodging | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-12-14 | ABBVIE INC. | $5 | Food and Beverage | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-12-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-12-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-11-23 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-11-06 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-11-06 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-10-28 | Janssen Pharmaceuticals, Inc | $14 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-10-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-10-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,607 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-10-08 | Eli Lilly and Company | $1,684 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2021 | |
| 2021-09-22 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-09-20 | Takeda Pharmaceuticals U.S.A., Inc. | $4,810 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-09-20 | Takeda Pharmaceuticals U.S.A., Inc. | $385 | Travel and Lodging | In-kind items and services | 2021 | ||
| 2021-09-20 | Takeda Pharmaceuticals U.S.A., Inc. | $123 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-09-13 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-09-13 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-09-07 | ABBVIE INC. | $1,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-09-07 | ABBVIE INC. | $57 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-09-07 | ABBVIE INC. | $14 | Food and Beverage | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-09-07 | ABBVIE INC. | $8 | Travel and Lodging | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-08-24 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-08-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-08-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-07-15 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-07-15 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-06-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-06-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-06-03 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-05-19 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-05-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-05-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-05-07 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-04-27 | Eli Lilly and Company | $6,430 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2021 | |
| 2021-04-12 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-04-12 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-04-09 | Takeda Pharmaceuticals U.S.A., Inc. | $433 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-03-26 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-03-08 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-03-08 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-03-04 | Janssen Pharmaceuticals, Inc | $14 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-02-11 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-02-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-02-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-01-21 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | TEFLARO Drug, ANTI-INFECTIVE | 2021 | |
| 2021-01-12 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-01-12 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2020-12-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,507 | Consulting Fee | Cash or cash equivalent | 2020 |
The latest 200 records of 396.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | Novartis Pharmaceuticals Corporation | COVENANT MEDICAL CENTER | $89 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2025 |
| 2025-08-19 | Novartis Pharmaceuticals Corporation | COVENANT MEDICAL CENTER | $2,744 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2025 |
| 2025-06-30 | Novartis Pharmaceuticals Corporation | COVENANT MEDICAL CENTER | $10,319 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2025 |
| 2025-06-24 | Eli Lilly and Company | MERCYONE WATERLOO MEDICAL CENTER | $1,251 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2025 |
| 2025-03-04 | Eli Lilly and Company | MERCYONE WATERLOO MEDICAL CENTER | $1,345 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2025 |
| 2025-02-11 | Eli Lilly and Company | MERCYONE WATERLOO MEDICAL CENTER | $55,111 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2025 |
| 2025-02-10 | Eli Lilly and Company | MERCYONE WATERLOO MEDICAL CENTER | $5,284 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2025-01-30 | Novartis Pharmaceuticals Corporation | MERCYONE WATERLOO MEDICAL CENTER | $6,164 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2025 |
| 2025-01-28 | Eli Lilly and Company | MERCYONE WATERLOO MEDICAL CENTER | $86,846 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2025-01-21 | Eli Lilly and Company | MERCYONE WATERLOO MEDICAL CENTER | $29,686 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2025 |
| 2024-07-09 | CSL Behring | Mercyone Waterloo Medical Center | $3,200 | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 |
| 2024-06-03 | CSL Behring | Mercyone Waterloo Medical Center | $8,512 | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 |
| 2024-04-01 | Novartis Pharmaceuticals Corporation | COVENANT MEDICAL CENTER | $20,381 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2024 |
| 2024-03-15 | CSL Behring | Mercyone Waterloo Medical Center | $3,000 | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 |
| 2024-03-15 | CSL Behring | Mercyone Waterloo Medical Center | $1,500 | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 |
| 2024-03-15 | CSL Behring | Mercyone Waterloo Medical Center | $1,600 | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 |
| 2024-03-01 | Novartis Pharmaceuticals Corporation | Mercyone Waterloo Medical Center | $7,628 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2024 |
| 2024-02-06 | Eli Lilly and Company | Mercyone Waterloo Medical Center | $225,154 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2024 |
| 2024-01-25 | Eli Lilly and Company | Mercyone Waterloo Medical Center | $4,143 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2024 |
| 2024-01-25 | Eli Lilly and Company | Mercyone Waterloo Medical Center | $4,164 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2024 |
| 2024-01-09 | Eli Lilly and Company | Mercyone Waterloo Medical Center | $2,737 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2024-01-02 | Eli Lilly and Company | Mercyone Waterloo Medical Center | $146,975 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2024-01-02 | Eli Lilly and Company | Mercyone Waterloo Medical Center | $363,933 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2024 |
| 2023-09-19 | Novartis Pharmaceuticals Corporation | COVENANT MEDICAL CENTER | $16,250 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2023 |
| 2023-07-11 | Eli Lilly and Company | MERCYONE WATERLOO MEDICAL CENTER | $2,244 | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 |
| 2023-05-09 | Eli Lilly and Company | MERCYONE WATERLOO MEDICAL CENTER | $168 | ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2023 |
| 2023-05-02 | Esperion Therapeutics, Inc. | MERCYONE WATERLOO MEDICAL CENTER | $15,026 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-03-31 | Novartis Pharmaceuticals Corporation | COVENANT MEDICAL CENTER | $3,989 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2023 |
| 2023-03-10 | Novartis Pharmaceuticals Corporation | MERCYONE WATERLOO MEDICAL CENTER | $14,375 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2023 |
| 2023-01-26 | Eli Lilly and Company | MERCYONE WATERLOO MEDICAL CENTER | $8,133 | ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER | 2023 |
| 2023-01-26 | Eli Lilly and Company | MERCYONE WATERLOO MEDICAL CENTER | $6,846 | A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | 2023 |
| 2023-01-18 | Esperion Therapeutics, Inc. | MERCYONE WATERLOO MEDICAL CENTER | $2,000 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-01-09 | Eli Lilly and Company | MERCYONE WATERLOO MEDICAL CENTER | $289,171 | ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER | 2023 |
| 2023-01-03 | Eli Lilly and Company | MERCYONE WATERLOO MEDICAL CENTER | $371,562 | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 |
| 2023-01-03 | Eli Lilly and Company | MERCYONE WATERLOO MEDICAL CENTER | $520,339 | A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | 2023 |
| 2022-08-28 | Eli Lilly and Company | Mercyone Waterloo Medical Center | $1,199 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $1,261 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $1,261 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-19 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-11 | Eli Lilly and Company | Mercyone Waterloo Medical Center | $5,628 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $50 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $82 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $82 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $82 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $82 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $105 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $82 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $82 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $82 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $82 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $105 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $105 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $105 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $105 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $50 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $50 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-05 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $50 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $1,261 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $1,261 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $1,261 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $1,261 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $1,261 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $1,261 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $1,261 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $1,261 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $338 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $338 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $586 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $586 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $586 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $586 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $586 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $1,261 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-08 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $1,261 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-24 | Esperion Therapeutics, Inc. | NORTHEAST IOWA MEDICAL EDUCATION FOUNDATION INC | $338 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-24 | Esperion Therapeutics, Inc. | NORTHEAST IOWA MEDICAL EDUCATION FOUNDATION INC | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-24 | Esperion Therapeutics, Inc. | NORTHEAST IOWA MEDICAL EDUCATION FOUNDATION INC | $226 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-24 | Esperion Therapeutics, Inc. | NORTHEAST IOWA MEDICAL EDUCATION FOUNDATION INC | $586 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-03 | Eli Lilly and Company | Mercyone Waterloo Medical Center | $315,458 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 |
| 2022-04-25 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $105 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-25 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $586 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-25 | Esperion Therapeutics, Inc. | Mercyone Waterloo Medical Center | $1,800 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-15 | Novartis Pharmaceuticals Corporation | COVENANT MEDICAL CENTER | $36,907 | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL, ASSESSING THE IMPACT OF INCLISIRAN ON MAJOR ADVERSE CAR | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | NORTHEAST IOWA MEDICAL EDUCATION FOUNDATION INC | $586 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | NORTHEAST IOWA MEDICAL EDUCATION FOUNDATION INC | $338 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Waterloo, IA, county Black Hawk County, IA, state Iowa; placed by its city name.
| Measure | Place (city or town) Waterloo, IA | County Black Hawk County, IA | State Iowa |
|---|---|---|---|
| Population B01003 | 67,008 | 131,049 | 3,210,507 |
| Population, 2020 census P1 | 67,314 | 131,144 | 3,190,369 |
| Median age B01002 | 36.7 | 35.7 | 38.6 |
| Under 18 B01001 | 24.5% | 21.9% | 22.9% |
| 65 and over B01001 | 17.0% | 17.7% | 18.1% |
| Households B11001 | 29,283 | 54,563 | 1,315,707 |
| Foreign born B05002 | 10.1% | 6.5% | 5.9% |
| Median household income B19013 | $57,480 | $66,417 | $75,059 |
| Median family income B19113 | $72,697 | $86,857 | $97,491 |
| Per capita income B19301 | $32,837 | $37,541 | $40,877 |
| Poverty rate B17001 | 16.6% | 14.9% | 11.1% |
| Unemployment rate B23025 | 5.3% | 4.6% | 3.6% |
| Civilian labor force B23025 | 34,281 | 70,124 | 1,699,994 |
| Mean commute (minutes) B08013 | 15.9 | 15.9 | 19.8 |
| Bachelor's degree or higher B15003 | 21.8% | 30.3% | 31.4% |
| Housing units B25001 | 32,143 | 58,991 | 1,437,699 |
| Owner-occupied B25003 | 62.1% | 66.2% | 71.7% |
| Renters B25003 | 37.9% | 33.8% | 28.3% |
| Median home value B25077 | $152,600 | $188,900 | $208,000 |
| Median gross rent B25064 | $923 | $989 | $972 |
| White, not Hispanic B03002 | 65.5% | 78.1% | 82.3% |
| Black B03002 | 16.4% | 9.1% | 3.8% |
| Hispanic or Latino B03002 | 8.4% | 5.2% | 7.3% |
| Asian B03002 | 3.2% | 2.7% | 2.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.2% |
Economy now FRED unemployment 3.2% in Sep 2026 (3.4% a year earlier); per capita personal income $67,321 in 2025, up 28% in five years (+2.8% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Waterloo, IA.
Comments